Trials / Conditions / Biliary Tract Cancer (BTC)

Biliary Tract Cancer (BTC)

20 registered clinical trials studyying Biliary Tract Cancer (BTC) — 16 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER NCT07515950	MedSIR	—
Not Yet Recruiting	Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Trac NCT07437287	UNICANCER	Phase 2 / Phase 3
Not Yet Recruiting	D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer NCT06622057	InnoPharmax Inc.	Phase 3
Recruiting	A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compar NCT07265674	J-Pharma Co., Ltd.	Phase 3
Recruiting	HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer NCT07466238	Peking University	N/A
Not Yet Recruiting	TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary T NCT07454486	Aarhus University Hospital	—
Recruiting	A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies NCT07197554	SEED Therapeutics, Inc.	Phase 1
Not Yet Recruiting	Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer NCT07129018	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 2
Not Yet Recruiting	In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of NCT07206355	University of Nottingham	—
Not Yet Recruiting	Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer NCT07169916	Fudan University	N/A
Not Yet Recruiting	A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary NCT07099794	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2
Not Yet Recruiting	Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma NCT06903273	National Cheng-Kung University Hospital	Phase 2
Not Yet Recruiting	Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced NCT06919848	Fudan University	Phase 2
Recruiting	Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With NCT05482893	Phanes Therapeutics	Phase 1 / Phase 2
Recruiting	Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer NCT07159204	Peking Union Medical College Hospital	Phase 2
Active Not Recruiting	The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer NCT05036486	National Health Research Institutes, Taiwan	—
Recruiting	Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818	I-Mab Biopharma US Limited	Phase 1
Terminated	A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Canc NCT03790111	TerSera Therapeutics LLC	Phase 2
Unknown	A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC NCT04004234	Chinese PLA General Hospital	Phase 1 / Phase 2
Completed	A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors NCT03314935	Incyte Corporation	Phase 1 / Phase 2